Dr. Krish Patel, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Duke University School of Medicine (2009)
- Years since graduation
- 17
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 122
Licensed in Washington since 2016, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Medical school: Duke University School of Medicine
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TN license 72470 · WA license MD60646130 (first issued 2016; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Swedish Medical Center Seattle, WA
- Tristar Centennial Medical Center Nashville, TN
- Tristar Skyline Medical Center Nashville, TN
Medical groups
- Verdi Oncology Tennessee PC (31 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 122
- Services billed
- 301
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 109 | 70 |
| Established patient office or other outpatient visit, 20-29 minutes | 96 | 71 |
| Established patient office or other outpatient visit, 40-54 minutes | 90 | 39 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 28 | 21 |
| New patient office or other outpatient visit, 60-74 minutes | 24 | 24 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Nashville, TN | 102 |
| Brukinsa (zanubrutinib) | 73 |
| Calquence (acalabrutinib maleate) | 70 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Nashville, TN | 60 |
| Prednisone Other prescribers in Nashville, TN | 30 |
| Ondansetron Odt (ondansetron) Other prescribers in Nashville, TN | 22 |
| Entecavir | 22 |
| Olanzapine Other prescribers in Nashville, TN | 20 |
| Prochlorperazine Maleate Other prescribers in Nashville, TN | 20 |
| Dexamethasone Other prescribers in Nashville, TN | 19 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 42 companies reported 132 payments worth $50,718 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $17,661 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $11,702 |
| Genentech USA, Inc. | $5,047 |
| AstraZeneca UK Limited | $4,100 |
| Beone Medicines USA, Inc. | $3,943 |
| AbbVie Inc. | $1,662 |
| Eli Lilly and Company | $1,305 |
| Lilly USA, LLC | $1,223 |
| Consulting Fee | $45,047 |
|---|---|
| Food and Beverage | $4,636 |
| Travel and Lodging | $1,035 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Oct 16, 2025 | Consulting Fee | $14,067 |
| AstraZeneca Pharmaceuticals LP Dec 12, 2025 | Consulting Fee CALQUENCE · Oncology | $5,740 |
| Genentech USA, Inc. Jun 6, 2025 | Consulting Fee | $4,920 |
| AstraZeneca UK Limited Apr 22, 2025 | Consulting Fee CALQUENCE · Oncology | $4,100 |
| AstraZeneca Pharmaceuticals LP Jul 22, 2025 | Consulting Fee CALQUENCE · Oncology | $2,460 |
| AstraZeneca Pharmaceuticals LP Oct 20, 2025 | Consulting Fee CALQUENCE · Oncology | $2,050 |
| Beone Medicines USA, Inc. Jul 28, 2025 | Consulting Fee BRUKINSA · Oncology | $2,000 |
| E.r. Squibb & Sons, L.l.c. May 15, 2025 | Consulting Fee | $1,910 |
| Beone Medicines USA, Inc. Dec 16, 2025 | Consulting Fee BRUKINSA · Oncology | $1,600 |
| AbbVie Inc. Apr 8, 2025 | Consulting Fee | $1,450 |
All 20 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Genmab U.S., Inc. Dec 18, 2025 | Consulting Fee Epkinly · Oncology | $800 |
| Beone Medicines USA, Inc. Dec 16, 2025 | Consulting Fee BRUKINSA · Oncology | $1,600 |
| AstraZeneca Pharmaceuticals LP Dec 16, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $1,230 |
| AstraZeneca Pharmaceuticals LP Dec 12, 2025 | Consulting Fee CALQUENCE · Oncology | $5,740 |
| Lilly USA, LLC Nov 7, 2025 | Consulting Fee JAYPIRCA · Oncology | $1,200 |
| AstraZeneca Pharmaceuticals LP Oct 20, 2025 | Consulting Fee CALQUENCE · Oncology | $2,050 |
| E.r. Squibb & Sons, L.l.c. Oct 16, 2025 | Consulting Fee | $14,067 |
| E.r. Squibb & Sons, L.l.c. Sep 3, 2025 | Travel and Lodging travel to Boston, MA | $387 |
| E.r. Squibb & Sons, L.l.c. Sep 3, 2025 | Travel and Lodging travel to Boston, MA | $203 |
| E.r. Squibb & Sons, L.l.c. Sep 3, 2025 | Travel and Lodging travel to Boston, MA | $37.74 |
| E.r. Squibb & Sons, L.l.c. Sep 3, 2025 | Travel and Lodging travel to Boston, MA | $19.98 |
| E.r. Squibb & Sons, L.l.c. Sep 2, 2025 | Travel and Lodging travel to Boston, MA | $387 |
| Merck Sharp & Dohme LLC Aug 20, 2025 | Consulting Fee IMMUNOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $320 |
| Beone Medicines USA, Inc. Jul 28, 2025 | Consulting Fee BRUKINSA · Oncology | $2,000 |
| AstraZeneca Pharmaceuticals LP Jul 22, 2025 | Consulting Fee CALQUENCE · Oncology | $2,460 |
| Genentech USA, Inc. Jun 6, 2025 | Consulting Fee | $4,920 |
| E.r. Squibb & Sons, L.l.c. May 15, 2025 | Consulting Fee | $1,910 |
| AstraZeneca UK Limited Apr 22, 2025 | Consulting Fee CALQUENCE · Oncology | $4,100 |
| AbbVie Inc. Apr 8, 2025 | Consulting Fee | $1,450 |
| Eli Lilly and Company Jan 14, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH RESEARCH RELATED SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,200 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 13 industry-funded studies in 2025, from 10 companies. The companies reported $1,096,951 in research payments for these studies, mostly to the institutions running them.
- A phase 1B2 openlabel study of PF07901801 in combination with glofitamab after a fixed single dose of obinutuzumab in participants with relapsedrefractory diffuse large b cell lymphoma not eligible for stem cell trans…
Pfizer Inc. - A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Eli Lilly and Company · Completed · NCT03740529 - A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC - Ph 1b of mosunetuzumab combined with lenalidomide in relapsed or refractory follicular lymphoma
F. Hoffmann-la Roche AG - A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA 2)
Kite Pharma, Inc. - Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
AbbVie Inc. · Active, not recruiting · NCT06667687 - An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Celgene Corporation - A phase 1B openlabel study of maplirpacept in combination with other anticancer treatments in adult participants with nonhodgkin lymphoma
Pfizer Inc. - A Phase 1b/2 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Relapsed/Refractory Multiple Myeloma
AstraZeneca Pharmaceuticals LP - A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA 7)
Kite Pharma, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.